Industrial Genomics

Whole Exome Sequencing (WES), Whole Genome Sequencing (WGS) and targeted panels, delivered at clinical grade.

From single-patient testing to large-scale newborn programs.

Four ways to leverage our infrastructure.

From rare disease diagnostics for individual patients to nationwide newborn screening programs, Breda Genetics delivers clinical-grade genomics through diagnostic services, sequencing capacity, ultra-fast workflows and direct scientific collaboration.

What sets us apart

Clinical-grade diagnostics.
WES, WGS and panels
with medical reporting
and expert interpretation.

High-quality sequencing
for laboratories with
in-house bioinformatics
and interpretation.

3-day exomes
for time-critical cases
requiring confident
clinical decisions.

Scalable genomic workflows
supporting regional and
national newborn screening
programs.

Four services. One clinical-grade laboratory.

Supporting rare disease diagnostics, routine and rapid NGS, and newborn screening programs.

Looking for WES/WGS outsourcing?

When rare disease diagnostics require end-to-end workflows with expert clinical reporting.

Need more sequencing capacity?

When demand grows faster than your laboratory can scale.

Need answers in 3 days?

When every day matters for clinical management.

Planning a newborn screening program?

Built on experience from over 4,000 newborn exomes in real-world screening programs.

It often starts with one case.

Many collaborations begin with a single patient or a single sample.
When trust grows, projects often grow with it.

Clinical sequencing
and diagnostic report.

From sample receipt
to final delivery.

NGS sequencing
without medical reporting.

Receive FASTQ files.
Run your own analysis.

3-day exome
for critical
timelines.

FASTQ in 3 days
Report in 5 days.

Newborn screening
at population
scale.

Scalable workflows
for thousands a year